NCT06876142 2026-04-16
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
Clinical Trials
9 trialsNCT04955808 2026-04-13
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
National Cancer Institute (NCI)
Suspended
NCT06348147 2026-02-17
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
UNC Lineberger Comprehensive Cancer Center
Phase 2 Suspended
NCT04661137 2026-02-10
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Suspended
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT04300335 2025-10-01
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Medical University of Vienna
Phase NA Suspended
NCT04505813 2024-01-16
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
NexImmune Inc.
Phase 1/2 Suspended
NCT03752541 2022-05-20
Efficacy and Safety Evaluation of BCMA-UCART
Bioray Laboratories
Phase NA Suspended
NCT00892346 2016-05-10
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Shanghai Jiao Tong University School of Medicine
Phase 3 Suspended